Comparison of anti-inflammatory effects of rivaroxaban versus dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study) -Multicenter randomized study

Trial Profile

Comparison of anti-inflammatory effects of rivaroxaban versus dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study) -Multicenter randomized study

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Dabigatran etexilate
  • Indications Arteriosclerosis; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms RIVAL-AF
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Aug 2016 Status changed from active, no longer recruiting to completed,according to the results presented at the ESC Congress 2016: Annual Congress of the European Society of Cardiology
    • 04 Aug 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Oct 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top